BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 29428472)

  • 21. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.
    Park JH; Ahn MY; Kim TH; Yoon S; Kang KW; Lee J; Moon HR; Jung JH; Chung HY; Kim HS
    Invest New Drugs; 2012 Oct; 30(5):1887-98. PubMed ID: 21983700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel cinnamohydroxamic acid derivatives as HDAC inhibitors with anticancer activity in vitro and in vivo.
    Wang L; Bao X; Yang J; Li H; Zhou Q; Jiang X; Li M; Liu X; Yuan X; Sun Y; Chen J; Zhang J; Chen G; Wu C
    Chem Biol Interact; 2016 Apr; 249():64-70. PubMed ID: 26944433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
    Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
    Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo.
    Liu S; Li F; Pan L; Yang Z; Shu Y; Lv W; Dong P; Gong W
    Cancer Sci; 2019 Aug; 110(8):2493-2506. PubMed ID: 31215139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
    Zhao N; Yang F; Han L; Qu Y; Ge D; Zhang H
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32046013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
    Duan W; Li J; Inks ES; Chou CJ; Jia Y; Chu X; Li X; Xu W; Zhang Y
    J Med Chem; 2015 May; 58(10):4325-38. PubMed ID: 25906087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
    Laurenzana A; Balliu M; Cellai C; Romanelli MN; Paoletti F
    PLoS One; 2013; 8(3):e58267. PubMed ID: 23469273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
    Cheng C; Yun F; Ullah S; Yuan Q
    Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S; Sankar R; Varunkumar K; Ravikumar V
    Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
    Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
    Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
    Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
    Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
    Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
    Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
    Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities.
    Ding J; Liu J; Zhang Z; Guo J; Cheng M; Wan Y; Wang R; Fang Y; Guan Z; Jin Y; Xie SS
    Bioorg Chem; 2020 Aug; 101():104023. PubMed ID: 32650178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.
    Yang B; Yu D; Liu J; Yang K; Wu G; Liu H
    Tumour Biol; 2015 Jul; 36(7):5051-61. PubMed ID: 25649979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
    Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of Non-Small Cell Lung Cancer Growth and Metastasis by a Novel Small Molecular Activator of RECK.
    Shen J; Wang B; Zhang T; Zhu N; Wang Z; Jin J; He Y; Hu M
    Cell Physiol Biochem; 2018; 45(5):1807-1817. PubMed ID: 29510387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
    Singh A; Chang TY; Kaur N; Hsu KC; Yen Y; Lin TE; Lai MJ; Lee SB; Liou JP
    Eur J Med Chem; 2021 Apr; 215():113169. PubMed ID: 33588178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
    Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
    Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.